Paediatric cancer hospital St. Jude Children's Research Hospital reported on Monday that it intends to develop a USD412m 625,000-square-foot advanced cancer research centre at its campus.
Slated to break ground in spring 2018 and open in 2021, the advanced research centre is a major component of the company's USD1bn capital expansion plans. The new centre will house cutting-edge technologies and resources that can transform science and accelerate the pace of discovery. The exploration and discovery centre will cultivate transformative research and collaboration and attract scientists and clinicians.
The company's new advanced research centre will treat childhood cancer and other life-threatening diseases. The interactive and interdisciplinary environment is designed specifically for generating new ideas and teamwork. Its labs and spaces will enable researchers to collaborate openly and across departments.
In addition, the company's new advanced research centre will feature state-of-the-art labs focusing on immunology, neurobiology, cell and molecular biology, gene editing, metabolomics, advanced microscopy, epigenetics, genomics, immunotherapy as well as RNA biology.
Developed by The Crump Firm, lead architect on the project and Jacobs Engineering, experts in lab design, the advanced research center propels St. Jude for the long term, accommodating growth for the next 20 years and beyond, with two of eight floors slated for future expansion and evolving technology.
Greenwich LifeSciences secures UK approval to expand Phase III breast cancer trial
Elephas Biosciences partners with Invitrocue to promote elive platform in Singapore and Malaysia
Lupin spins out two oncology programmes to Kaveri Therapeutics
Fuse Oncology launches new prescribing and treatment-intent solution FuseRx
Tempus agrees to acquire Personalis in USD1.5bn precision oncology deal
Evaxion to present three-year cancer vaccine data at ESMO Congress 2026
Raidium introduces AI-powered oncology imaging workflow for US cancer centres
Galmed announces breakthrough development of SCD1 inhibitor Aramchol for cardiac fibrosis
Intensity Therapeutics restarts breast cancer Phase 2 clinical trial
Merck reports positive Phase 3 results for KEYTRUDA in advanced endometrial cancer
Kelun-Biotech's Phase III study of sac-TMT in combination with pembrolizumab meets primary endpoint
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
Summit Therapeutics sells Phase III antibiotic asset ridinilazole to Biossil
European Commission approves Erbitux combination for first-line BRAF V600E-mutant mCRC